Calcium phosphate nanoparticle preparation, gene delivery, and immunotherapy for melanoma

​Yilun Wu is focusing on developing lipid-coated calcium phosphate/carbonate (LCCP) nanoparticles (NPs) for effective siRNA delivery in melanoma immunotherapy by silencing PD-L1 gene. Queensland State, “the capital of melanoma”, has the highest prevalence of melanoma around the world. Conventional treatments such as chemotherapy and radiotherapy can cause side effects. So finding an efficient treatment for late stage melanoma is of great importance, where immunotherapy is one of the promising approaches. To overcome tumour tolerance to the immune system, one effective approach is to suppress the Programmed cell death ligand-1 (PD-L1) with siRNA. Herein, LCCP NPs are designed as novel siRNA delivery platforms for knockdown of PD-L1 gene, as well as switch-off of upstream genes. Successfully completing this project may provide a novel nanoparticle-based siRNA delivery approach for melanoma immunotherapy.

​2015.7- present, the University of Queensland, Australia. PhD candidate. nternational Postgraduate Research Scholarship (IPRS) and UQ Centennial Scholarship (UQCent) in Australia 09.2012-03.2015, Donghua University, Shanghai, P.R.China. Master of Engineering. Full Scholarship at Donghua University, China Patent CN102784397 B 09.2008-06.2012, Donghua University, Shanghai, P.R.China. Bachelor of Engineering. Donghua University Scholarship, Outstanding Undergraduate Dissertations


​Yilun Wu collaborated with Shanghai No. 1 People's Hospital in targeted drug delivery in mouse model, and Shanghai No. 10 People's Hospital in CT/MR dual model imaging.


Host of Innovation Fund of Donghua University Master Dissertation of Excellence

Key Publications

  1. Yilun Wu, Rui Guo, Shihui Wen, et al., Folic acid-modified laponite nanodisks for targeted anticancer drug delivery, Journal of Materials Chemistry B, 2014, 2, 7410–7418
  2. Shige Wang, Yilun Wu, Rui Guo, et al., Laponite nanodisks as an efficient platform for doxorbicin delivery to cancer cells, Langmuir, 2013, 29, 5030-5036. (IF = 4.384, : the authors contributed equally to the work)
  3. Fanfan Fu, Yilun Wu, Jingyi Zhu, et al., Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: Investigating the role played by PEG spacer, ACS Applied Materials & Interfaces, 2014, 6, 16416−16425
  4. Guoying Wang, Dina Maciel, Yilun Wu, et al., Amphiphilic polymer-mediated formation of laponite®-based nanohybrids with robust stability and pH sensitivity for anticancer drug delivery, ACS Applied Materials & Interfaces, 2014, 6, 16687−16695. (IF = 5.900) Patent (China) Xiangyang Shi, Yilun Wu, Shige Wang, et al., CN102784397 B.